Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 2

Conditions

Myeloproliferative Disorders 2Anemia 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 7fludarabine 6Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6ruxolitinib 5fludarabine phosphate 5Melphalan 5venetoclax 4Peripheral Blood Stem Cell Transplantation 4itacitinib 3Specimen Handling 3Sirolimus 3Granulocyte Colony-Stimulating Factor 3Cytarabine 3Biopsy 3Azacitidine 3navitoclax 2luspatercept 2Etoposide 2Daunorubicin 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1selinexor 1quizartinib 1pomalidomide 1plerixafor 1pevonedistat 1parsaclisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Myeloproliferative Disorders × luspatercept × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡